<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336052">
  <stage>Registered</stage>
  <submitdate>1/10/2010</submitdate>
  <approvaldate>25/10/2010</approvaldate>
  <actrnumber>ACTRN12610000900011</actrnumber>
  <trial_identification>
    <studytitle>High and low dose oxytocin for augmentation of labor</studytitle>
    <scientifictitle>The effects of high versus low dose oxytocin on cesarean section rate, fetal and maternal outcomes for augmentation of labor in pregnant women gestational age &gt; 37 weeks</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Effect of oxytocin for augmentation of labor</healthcondition>
    <healthcondition>Cesarean section rate</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Normal pregnancy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: High dose oxytocin infusion (4 mU/minute and increase the rate by 4 mU/ml every 30 minutes with maximum dose not exceed 16 mU/ml (oxytocin 10 units in isotonic solution 1,000 ml) 
Arm 2: Low dose oxytocin infusion 2 mU/minute and increase the rate by 2 mU/ml every 30 minutes with maximum dose not exceed 16 mU/ml (oxytocin 10 units in isotonic solution 1,000 ml)</interventions>
    <comparator>Arm 2:Low dose oxytocin infusion (2 mU/minute and increase the rate by 2 mU/ml every 30 minutes with maximum dose not exceed 16 mU/ml (oxytocin 10 units in isotonic solution 1,000 ml)</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary outcome: Cesarean section rate, will be assessed by medical records</outcome>
      <timepoint>Time point: at one year after randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary outcome: Fetal and maternal outcome, will be assessed by medical records</outcome>
      <timepoint>Time point: at one year after randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Mother criteria
1. Singleton, gestational age 37 weeks or more
2. Vertex presentation
3. Bishop score = 9 or more
4. Inadequate uterine contraction
Child criteria
1. Viable fetus
2. Singleton
3. Vertex presentation
4. well being fetus</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Contraindication for augmentation of labor e.g. malposition, placenta previa,   prior uterine scar, overdistended uterus, grand multiparity
2. Cephalopelvic disproportion (CPD)
3. Dead fetus in utero (DFIU)
4. Contraindication in using oxytocin e.g. allergy to oxytocin, low blood pressure, fetal distress
5. Medical complications: hypertension, HIV infection, coagulopathy, diabetes mellitus, heart diseases</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment using sealed opaque envelopes</concealment>
    <sequence>Simple randomization using a randomization table created by computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/11/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Suppasiri Hayakungchat</primarysponsorname>
    <primarysponsoraddress>Khon Kaen Hospital
Srichan Road
Muang District
Khon Kaen Province
40000</primarysponsoraddress>
    <primarysponsorcountry>Thailand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Khon Kaen Hospital</fundingname>
      <fundingaddress>Srichan Road
Muang District
Khon Kaen Preovince
40000</fundingaddress>
      <fundingcountry>Thailand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Ussanee Sangkhomkamhang Swadpanich</sponsorname>
      <sponsoraddress>Khon Kaen Hospital
Srichan Road
Muang District
Khon Kaen Province
40000</sponsoraddress>
      <sponsorcountry>Thailand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dystocia is the most common cause of cesarean section in primigravida, This would be improved by adequate augmentation of labor. The augmentation methods included amniotomy, prostaglandins or oxytocin adminiatration. Intravenous oxytocin infusion was a commonly method used for augmentation of labor, but standard regimen is still inconclusive. The prior study reported that high dose oxytocin was significantly decrease cesarean section rate without serious maternal and fetal complications when compared to low dose oxytocin. However, some studies showed that high dose was not superior to low dose in augmentation of labor but only shorten delivery time. After we intensively searched and reviewed the literature, we found that no prior study has been conducted  in Thailand. We therefore would like to study the effectiveness and safety of high dose oxytocin in augmentation of labor when compared to low dose oxytocin. The primary endpoint is cesarean section rate and the secondary endpoints are duration of delivery and maternal and fetal complications.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Ethics Committee for Research in Human Subjects, Khon Kaen Hospital</ethicname>
      <ethicaddress>Srichan Road
Muang District
Khon Kaen Province
40000</ethicaddress>
      <ethicapprovaldate>22/09/2010</ethicapprovaldate>
      <hrec>75/01/2553</hrec>
      <ethicsubmitdate>2/08/2010</ethicsubmitdate>
      <ethiccountry>Thailand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ussanee Sangkhomkamhang Swadpanich</name>
      <address>Khon Kaen Hospital
Srichan Road
Muang District
Khon Kaen Province
40000</address>
      <phone>+66812619299</phone>
      <fax>+6643336789 Ext.3736</fax>
      <email>swadpanich@hotmail.com</email>
      <country>Thailand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Suppasiri Hayakungchat</name>
      <address>Khon Kaen Hospital
Srichan Road
Muang District
Khon Kaen Province
40000</address>
      <phone>+66813781283</phone>
      <fax>+6643336789 Ext.3736</fax>
      <email>palmy138@gmail.com</email>
      <country>Thailand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Suppasiri Hayakungchat</name>
      <address>Khon Kaen Hospital
Srichan Road
Muang District
Khon Kaen Province
40000</address>
      <phone>+66813781283</phone>
      <fax>+6643336789 Ext.3736</fax>
      <email>palmy138@gmail.com</email>
      <country>Thailand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>